Evidence map›Paper›PMID 40497373›Full record

ArticleCancer medicine2025

Oral Combined Probiotics Clostridium butyricum and Akkermansia muciniphila Inhibits the Progression of 4T1 Breast Cancer by Activating Bcl-2/Bax Pathway.

Xiaowei Li, Dengxiong Hua, Daoyan Wu, Wei Hong, Yingqian Kang, Lei Tang, Qin Yang, Xinxin Wang, Boyan Li, Renmin Li and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Xiaowei LiKey Laboratory of Microbiology and Parasitology of Education Department of Guizhou & Key Laboratory of Medical Molecular Biology of Guizhou Province, Guizhou Medical University, Guiyang, China.
Dengxiong HuaKey Laboratory of Microbiology and Parasitology of Education Department of Guizhou & Key Laboratory of Medical Molecular Biology of Guizhou Province, Guizhou Medical University, Guiyang, China.
Daoyan WuKey Laboratory of Microbiology and Parasitology of Education Department of Guizhou & Key Laboratory of Medical Molecular Biology of Guizhou Province, Guizhou Medical University, Guiyang, China.
Wei HongKey Laboratory of Microbiology and Parasitology of Education Department of Guizhou & Key Laboratory of Medical Molecular Biology of Guizhou Province, Guizhou Medical University, Guiyang, China.
Yingqian KangKey Laboratory of Microbiology and Parasitology of Education Department of Guizhou & Key Laboratory of Medical Molecular Biology of Guizhou Province, Guizhou Medical University, Guiyang, China.
Lei TangGuizhou Provincial Engineering Technology Research Center for Chemical Drug R&D, Guizhou Medical University, Guiyang, China.
Qin YangKey Laboratory of Microbiology and Parasitology of Education Department of Guizhou & Key Laboratory of Medical Molecular Biology of Guizhou Province, Guizhou Medical University, Guiyang, China.
Xinxin WangKey Laboratory of Microbiology and Parasitology of Education Department of Guizhou & Key Laboratory of Medical Molecular Biology of Guizhou Province, Guizhou Medical University, Guiyang, China.
Boyan LiSchool of Public Health, Guizhou Medical University, Guiyang, China.
Renmin LiStandard Testing Group Co., Ltd., Qingdao, China.
Zhenghong ChenKey Laboratory of Microbiology and Parasitology of Education Department of Guizhou & Key Laboratory of Medical Molecular Biology of Guizhou Province, Guizhou Medical University, Guiyang, China.
Guzhen CuiKey Laboratory of Microbiology and Parasitology of Education Department of Guizhou & Key Laboratory of Medical Molecular Biology of Guizhou Province, Guizhou Medical University, Guiyang, China.ORCID https://orcid.org/0000-0002-6520-1052

Funding

111 Project D20009Excellent Young Talent Program of Guizhou Medical University (2022)112Guizhou Health Commission Project 2025GZWJKJXM0153Guizhou Key Laboratory ZDSYS[2023]004High-Level Innovation Talent Project of Guizhou GCC[2022]036-1High-Level Innovation Talent Project of Guizhou GCC[2023]002Local Science Foundation of Guizhou Province Guided by the Central Committee of China Qiankehe[2025]024Major Science and Technology Projects of China Tobacco 110202101048[LS-08]National Natural Science Foundation of China 32160015Science and Technology Research Project for Guizhou ZK[2022]-388Scientists Workstation Guizhou Province KXJZ[2024]009
6 · The paper itself

Abstract

backgroundBreast cancer is the most common malignant tumor among women. Recent studies have found that gut probiotics and their metabolic products play a significant role in activating the immune system, reshaping the tumor microenvironment, and inhibiting cancer progression.

methodsWe established a 4T1 tumor-bearing mice model and analyzed the proportions of CD4

resultsThe results indicated that oral administration of CB and AKK possesses the capability to inhibit the progression of 4T1 breast cancer; however, the combined treatment with both strains (CB-AKK) exhibited significantly superior effects compared to each individual strain. Further mechanistic analysis revealed that the CB-AKK combination could activate the antitumor immunity in mice and reshape the tumor microenvironment. Additionally, it was found that the live bacteria and their metabolites derived from CB-AKK could inhibit cell proliferation and promote tumor apoptosis by activating the Bcl-2/Bax signaling pathway.

conclusionThis study is the first to demonstrate that orally administered live bacteria CB-AKK can inhibit the progression of 4T1 breast cancer, providing a promising new strategy for the development of innovative biotherapies for breast cancer.

Indexed as

Akkermansiabcl-2-Associated X ProteinBreast NeoplasmsClostridium butyricumProbioticsProto-Oncogene Proteins c-bcl-2Administration, OralAnimalsApoptosisCell Line, TumorCell ProliferationDisease ProgressionFemaleHumansMiceMice, Inbred BALB CBax protein, mousebcl-2-Associated X ProteinBcl2 protein, mouseProto-Oncogene Proteins c-bcl-2Akkermansia muciniphilaapoptosisBcl‐2/Bax signaling pathwaybreast cancerClostridium butyricumprobiotics

Identifiers

PMID40497373
PMCPMC12152643

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.